Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2169692 | 1.00 | SPHK1 (0.69) | SPHK1SPHK2 | |
| SCHEMBL4926619 | 1.00 | SPHK1 (0.69) | SPHK1SPHK2 | |
| Biphenyl SCHEMBL27478734 | 0.95 | SPHK1 (0.64) | SPHK1SPHK2 | |
| SCHEMBL1257009 | 0.95 | SPHK1 (0.64) | SPHK1SPHK2 | |
| SCHEMBL6342866 | 0.95 | SPHK1 (0.64) | SPHK1SPHK2 | |
| SCHEMBL1051602 | 0.95 | SPHK1 (0.64) | SPHK1SPHK2 | |
| Acetic Acid SCHEMBL7451806 | 0.92 | SPHK1 (0.62) | SPHK1SPHK2 | |
| SCHEMBL2269998 | 0.91 | SPHK1 (0.63) | SPHK1SPHK2 | |
| SCHEMBL12530064 | 0.91 | SPHK1 (0.63) | SPHK1SPHK2 | |
| SCHEMBL7576557 | 0.89 | GBA1 (0.59) | SPHK1SPHK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 254 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060270847-A1 | Process for producing nitrogenous heterocyclic compound | TORAY FINE CHEMICALS CO., LTD. (JP) | 2006-11-30 | — | — | US | claimed |
| EP-1640364-A1 | PROCESS FOR PRODUCING NITROGENOUS HETEROCYCLIC COMPOUND | Toray Fine Chemicals Co., Ltd. (JP) | 2006-03-29 | — | — | EP | claimed |
| US-12630566-B2 | KRas G12D inhibitors | Mirati Therapeutics, Inc. (US) | 2026-05-19 | — | — | US | disclosed |
| EP-3653618-B1 | NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2025-01-08 | — | — | EP | disclosed |
| US-20240309020-A1 | KRAS G12D INHIBITORS | ARRAY BIOPHARMA INC. | 2024-09-19 | — | — | US | disclosed |
| CN-111989321-B | KRAS G12C inhibitors | 米拉蒂治疗股份有限公司 | 2024-05-14 | — | — | CN | disclosed |
| US-11964989-B2 | KRas G12D inhibitors | Mirati Therapeutics, Inc. (US) | 2024-04-23 | — | — | US | disclosed |
| CN-117917416-A | KRAS G12D degradation agent and preparation method and application thereof | 上海领泰生物医药科技有限公司 | 2024-04-23 | — | — | CN | disclosed |
| CN-114615981-B | KRAS G12D inhibitors | 米拉蒂治疗股份有限公司 | 2024-04-12 | — | — | CN | disclosed |
| US-20240101553-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2024-03-28 | — | — | US | disclosed |
| US-20230373999-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-11-23 | — | — | US | disclosed |
| EP-1137412-A2 | SUBSTITUTED NITROGEN HETEROCYCLIC COMPOUNDS AND THERAPEUTIC USES THEREOF | AMERICAN BIOGENETIC SCIENCES, INC. (US) | 2001-10-04 | — | — | EP | disclosed |
| EP-1114027-A1 | THE PREPARATION OF N-SUBSTITUTED-HYDROXYCYCLOALKYLAMINE DERIVATIVES | Samsung Fine Chemicals Co., Ltd. (KR) | 2001-07-11 | — | — | EP | disclosed |
| WO-2000037458-A1 | FARNESYL PROTEIN TRANSFERASE INHIBITORS | SCHERING CORPORATION (US) | 2000-06-29 | — | — | WO | disclosed |
| WO-2000033788-A2 | SUBSTITUTED NITROGEN HETEROCYCLIC COMPOUNDS AND THERAPEUTIC USES THEREOF | AMERICAN BIOGENETIC SCIENCES INC. (US) | 2000-06-15 | — | — | WO | disclosed |
| WO-2000015610-A1 | THE PREPARATION OF N-SUBSTITUTED-HYDROXYCYCLOALKYLAMINE DERIVATIVES | SAMSUNG FINE CHEMICALS CO., LTD. (KR) | 2000-03-23 | — | — | WO | disclosed |
| EP-0912512-A1 | SULPHONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CNS DISORDERS | SMITHKLINE BEECHAM PLC (GB) | 1999-05-06 | — | — | EP | disclosed |
| WO-1997048681-A1 | SULPHONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CNS DISORDERS | SMITHKLINE BEECHAM PLC (GB) | 1997-12-24 | — | — | WO | disclosed |
| EP-0757051-A1 | PENEM DERIVATIVES AND ANTIMICROBIAL AGENT CONTAINING THE SAME | SUNTORY LIMITED (JP) | 1997-02-05 | — | — | EP | disclosed |
| US-5051420-A | Treatment of cardiovascular disorders | A. H. ROBINS COMPANY, INCORPORATED (US) | 1991-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630566-B2 | KRas G12D inhibitors | KRAS, NRAS, HRAS | SPHK1 256/4885SPHK2 328/4885 |
| US-20240101553-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | SPHK1 2769/4885SPHK2 2756/4885 |
| US-20060270847-A1 | Process for producing nitrogenous heterocyclic compound | HNMT, HRH4, QDPR | SPHK1 3056/4885SPHK2 3675/4885 |
| US-11964989-B2 | KRas G12D inhibitors | KRAS, NRAS, HRAS | SPHK1 2065/4885SPHK2 2198/4885 |
| US-20240309020-A1 | KRAS G12D INHIBITORS | KRAS, NRAS, HRAS | SPHK1 3100/4885SPHK2 2989/4885 |
| US-20230373999-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | SPHK1 2769/4885SPHK2 2756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.